Automated ‘oscillometric’ blood pressure measuring devices: how they work and what they measure

Sharman, James E.; Tan, Isabella; Stergiou, George S.; Lombardi, Carolina; Saladini, Francesca; Butlin, Mark; Padwal, Raj; Asayama, Kei; Avolio, Alberto; Brady, Tammy M.; Murray, Alan; Parati, Gianfranco

doi:10.1038/s41371-022-00693-x

Cited by 27 publications

(17 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both the XCEL and Mobil-O-Graph methods record cuff BP using a standard, noninvasive automated technique in which BP is estimated using proprietary algorithms during a single cuff inflation and deflation cycle. 32 Immediately after measurement of standard cuff BP, each device reinflates the cuff to record peripheral pressure waveforms and estimate central BP by application of proprietary generalized transfer functions. 33 All BP data were electronically downloaded from the BP monitors.…”

Section: Methodsmentioning

confidence: 99%

Blood Pressure Lowering in Patients With Central Hypertension: A randomized Clinical Trial

Sharman,

Otahal,

Stowasser

et al. 2024

Hypertension

View full text Add to dashboard Cite

BACKGROUND: Cuff blood pressure (BP) is recommended for guiding hypertension management. However, central BP has been proposed as a superior clinical measurement. This study aimed to determine whether controlling hypertension as measured by central BP was beneficial in reducing left ventricular mass index beyond control of standard cuff hypertension. METHODS: This multicenter, open-label, blinded-end point trial was conducted in individuals treated for uncomplicated hypertension with controlled cuff BP (<140/90 mm Hg) but elevated central BP (≥0.5 SD above age- and sex-specific normal values). Participants were randomized to 24-months intervention with spironolactone 25 mg/day (n=148) or usual care control (n=153). The primary outcome was change in left ventricular mass index measured by cardiac MRI. Cuff and central BPs were measured by clinic, 7-day home and 24-hour ambulatory BPs. RESULTS: At 24-months, there was a greater reduction in left ventricular mass index (−3.2 [95% CI, −5.0 to −1.3] g/m 2 ; P =0.001) with intervention compared with control. Cuff and central BPs were lowered by a similar magnitude across all BP measurement modes (eg, clinic cuff systolic BP, −6.16 [−9.60 to −2.72] mm Hg and clinic central systolic BP, −4.96 [−8.06 to −1.86] mm Hg; P ≥0.48 all). Secondary analyses found that changes in left ventricular mass index correlated to changes in BP, with the magnitude of effect nearly identical for BP measured by cuff (eg, 24-hour systolic BP, β, 0.17 [0.02–0.31] g/m 2 ) or centrally (24-hour systolic BP, β, 0.16 [0.01–0.32] g/m 2 ). CONCLUSIONS: Among individuals with central hypertension, spironolactone had beneficial effects in reducing LV mass. Secondary analyses showed that changes in LV mass were equally well associated with lower measured standard cuff BP and central BP. REGISTRATION: URL: https://www.anzctr.org.au/ ; Unique identifier: ACTRN12613000053729

show abstract

Section: Methodsmentioning

confidence: 99%

Blood Pressure Lowering in Patients With Central Hypertension: A randomized Clinical Trial

Sharman,

Otahal,

Stowasser

et al. 2024

Hypertension

View full text Add to dashboard Cite

show abstract

“…Going a step further, blood pressure studies and clinical applications are entering the digital era in patient monitoring through digital devices and wearables. Novel approaches in digital monitoring combine algorithms of high precision and of great value for CVDs chronic patients 322,323 . These algorithms can detect CV risks for hypertensive patients with continuous, noninvasive measurements of blood pressure and are becoming key tools for chronic patient management (Figure 5D).…”

Section: Clinical Practice and Development Of New Technologies In Mec...mentioning

confidence: 99%

“…Novel approaches in digital monitoring combine algorithms of high precision and of great value for CVDs chronic patients. 322,323 These algorithms can detect CV risks for hypertensive patients with continuous, noninvasive measurements of blood pressure and are becoming key tools for chronic patient management (Figure 5D).…”

Section: Agingmentioning

confidence: 99%

Advances in mechanical biomarkers

Eroles

Rico

2023

J of Molecular Recognition

View full text Add to dashboard Cite

Mechanical biomarkers distinguish health conditions through quantitative mechanical measurements. The emergence and establishment of nanotechnology in the last decades have provided new tools to obtain mechanical biomarkers at the nanoscale.Mechanical measurements are reproducible, label-free, start to be applied in vivo can be high throughput, and require small samples. Mechanical protocols in clinical practice at the macro scale like palpation or blood pressure measurement are routinely used by medical doctors. Nanotechnology brought mechanical sensing to the next scale, where cells, tissues, and proteins can be probed and linked to medical conditions. Mechanical changes in cells and tissues may be detected before other markers, such as protein expression, providing an important advantage as biomarkers. In the present review, we explore the biomarker's historical evolution, describe mechanical biomarkers on various diseases and novel discoveries in the nanomechanical field for their characterization. We conclude that mechanical biomarkers are establishing novel hallmarks in diseases, in several cases for early diagnostics of diseases and discovery of drug targets in the proteins involved in the mechanical changes, while advances in instrumentation are bringing commercial products into the clinical practice. Mechanical biomarkers along with clinical testing are establishing an important niche in the market, whose demand is increasing due to the expansion of personalized medicine and unmet needs in the clinics.

show abstract

“…Клинических наблюдений, относящихся ко второму типу и опубликованных в литературе, много. Выделяют 2 подтипа: тип IIa, когда ткань присутствует на самой митральной створке [3,4]; и тип IIb, когда ткань имеет прикрепление на субаортальном уровне межжелудочковой перегородки [7,12] или даже аортальном клапане [13,14]. Но не над митральным клапаном, то есть не в предсердии.…”

Section: второй тип по анатомо-клинической классификацииunclassified

Accessory Mitral Valve Tissue in the Internist’s Practice

Posokhov¹

2022

A.I. Burnasyan Federal Medical Biophysical Center Clinical Bull

View full text Add to dashboard Cite

Attention to the topic of accessory mitral valve tissue intense in the 90s. After that, it would seem that interest began to fade, however, at present it has begun to increase again according the number of reviews found in MedLine. ‘What is the reason for the increased interest’, ‘what is the current state of art’ these questions were the background for this review. This lecture summarizes new knowledge about mitral valve accessory tissue and makes it clear that it is important to physicians in many specialties including internists.

show abstract

Automated ‘oscillometric’ blood pressure measuring devices: how they work and what they measure

Cited by 27 publications

References 63 publications

Blood Pressure Lowering in Patients With Central Hypertension: A randomized Clinical Trial

Blood Pressure Lowering in Patients With Central Hypertension: A randomized Clinical Trial

Advances in mechanical biomarkers

Accessory Mitral Valve Tissue in the Internist’s Practice

Contact Info

Product

Resources

About